Literature DB >> 14513045

Vascular endothelial growth factor and its receptors in multiple myeloma.

R Ria1, A M Roccaro, F Merchionne, A Vacca, F Dammacco, D Ribatti.   

Abstract

Multiple myeloma (MM) progresses from an avascular to a vascular phase (active MM) accompanied by a significant increase in microvessel density in the bone marrow. This article summarizes the literature concerning the specific role played by vascular endothelial growth factor (VEGF) in this process. Recent applications of antiangiogenic agents that interfere with VEGF signaling and block MM progression are also described.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14513045     DOI： 10.1038/sj.leu.2403076

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  12 in total

1.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

2.  Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Yuanjian Chen; Robert A Ahokas; Yao Sun
Journal:  Microvasc Res       Date:  2010-04-01       Impact factor: 3.514

3.  Lentivirus-mediated RNAi knockdown of VEGFA in RKO colorectal cancer cells decreases tumor formation and growth in vitro and in vivo.

Authors:  Jiang-Feng Qiu; Zhi-Qi Zhang; Yong Wang; Jun You
Journal:  Int J Clin Exp Pathol       Date:  2011-04-30

4.  Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

Authors:  Irma Airoldi; Claudia Cocco; Nicola Giuliani; Marina Ferrarini; Simona Colla; Emanuela Ognio; Giuseppe Taverniti; Emma Di Carlo; Giovanna Cutrona; Vittorio Perfetti; Vittorio Rizzoli; Domenico Ribatti; Vito Pistoia
Journal:  Blood       Date:  2008-05-12       Impact factor: 22.113

5.  Curative one-shot systemic virotherapy in murine myeloma.

Authors:  S Naik; R Nace; M J Federspiel; G N Barber; K-W Peng; S J Russell
Journal:  Leukemia       Date:  2012-03-19       Impact factor: 11.528

6.  Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.

Authors:  Maria Gkotzamanidou; Dimitrios Christoulas; Vasillis L Souliotis; Athanasios Papatheodorou; Meletios A Dimopoulos; Evangelos Terpos
Journal:  Med Sci Monit       Date:  2013-12-20

7.  Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.

Authors:  O Jung; V Trapp-Stamborski; A Purushothaman; H Jin; H Wang; R D Sanderson; A C Rapraeger
Journal:  Oncogenesis       Date:  2016-02-29       Impact factor: 7.485

8.  Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.

Authors:  Claudia Greco; Gaetano Vitelli; Giuseppe Vercillo; Rosa Vona; Diana Giannarelli; Isabella Sperduti; Francesco Pisani; Ettore Capoluongo; Maria Concetta Petti; Franco Ameglio
Journal:  J Exp Clin Cancer Res       Date:  2009-03-10

Review 9.  The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer.

Authors:  Xiaoxia Zhu; Wen Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2015-10-09       Impact factor: 5.555

Review 10.  Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.

Authors:  Jinheng Wang; Sylvia Faict; Ken Maes; Elke De Bruyne; Els Van Valckenborgh; Rik Schots; Karin Vanderkerken; Eline Menu
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.